PATENT CLAIM ANALYSIS

Application Number: 15867177
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["424", "248100"]

Abstract:
The present invention provides novel therapeutic applications of low dose naltrexone (LDN). Said applications have been determined in light of the discovery by the present inventors that naltrexone acts as an antagonist of Toll-like receptor 9 (TLR9), an innate immune receptor which elicits the production of inflammatory cytokines when agonised. Chronic inflammation and TLR9 overexpression are characteristics of a number of disorders, including certain cancers. Accordingly, the present invention provides novel uses of naltrexone in the treatment of a subject having a disorder characterised by TLR9 overexpression and/or overactivity of TLR9-mediated signalling. The present invention also provides novel uses of naltrexone in the supportive care of subject having a tumour/cancer, and methods of treating and providing supportive care to a subject, comprising the administration of naltrexone.

Claim (Index 9):
A pharmaceutical composition according to  claim 8 , wherein macrophages; B cells; and/or dendritic cells, preferably plasmacytoid dendritic cells; of the subject are characterised as having TLR9 overexpression.

Metadata:
- Claim Count in Document: 56.0
- Percentile: 86.0
- Lexical Diversity: 1.81818
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14890300', '15437365', '14351766', '15162535', '14892973']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6936466883559155
- 35 USC 102 Novelty (BERT): 0.5410720352223035
- Combined Prediction Score: 0.6783892230425542
- Mean Citation Score: 223.850238
- Max Citation Score: 389.5803
- Similarity Product: 224.45740972681045

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test